Articles by Kerstin Folkerts, MSc
Validation of the FINE-CKD Model for Future Health Technology Assessments for Finerenone in Patients With Chronic Kidney Disease And Type 2 Diabetes
ByMichał Pochopień, MSc,David Z. I. Cherney, MD, PhD,Aleksandra Drzewiecka, MSc,Kerstin Folkerts, MSc,Pierre Levy, PhD,Aurélie Millier, PhD,Stephen Morris, PhD,Monika Palarczyk, MSc,Prabir Roy-Chaudhury, MD, PhD,Sean D. Sullivan, PhD,Paul Mernagh, MCom ACE Inhibitor or ARB Treatment Among Patients With Diabetes and Chronic Kidney Disease
ByLinda F. Fried, MD, MPH,Natalia Petruski-Ivleva, PhD,Kerstin Folkerts, MSc,Niklas Schmedt, DrPH,Priscilla Velentgas, PhD,Csaba P. Kovesdy, MD FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes
ByMichał Pochopień, MSc,David Z. I. Cherney, MD, PhD,Kerstin Folkerts, MSc,Pierre Levy, PhD,Aurélie Millier, PhD,Stephen Morris, PhD,Prabir Roy-Chaudhury, MD, PhD,Sean D. Sullivan, PhD,Paul Mernagh, MCom eAppendix: ACE Inhibitor or ARB Treatment Among Patients With Diabetes and Chronic Kidney Disease
ByLinda F. Fried, MD, MPH,Natalia Petruski-Ivleva, PhD,Kerstin Folkerts, MSc,Niklas Schmedt, DrPH,Priscilla Velentgas, PhD,Csaba P. Kovesdy, MD eAppendix: FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes
ByMichał Pochopień, MSc,David Z. I. Cherney, MD, PhD,Kerstin Folkerts, MSc,Pierre Levy, PhD,Aurélie Millier, PhD,Stephen Morris, PhD,Prabir Roy-Chaudhury, MD, PhD,Sean D. Sullivan, PhD,Paul Mernagh, MCom Targeted Literature Review of the Burden of Illness in Patients With Chronic Kidney Disease and Type 2 Diabetes
ByLinda F. Fried, MD, MPH,Kerstin Folkerts, MSc,Beata Smela, MSc,Kevin Deon Bowrin, MSc,Paul Mernagh, MCom,Aurelie Millier, PhD,Csaba P. Kovesdy, MD